Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

(AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 ... Advertisement Article continues below this ad The life science technology company posted revenue of $165 million in the period, ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...

Biotech company 10x Genomics (NASDAQ:TXG ... and sequencing companies within the life sciences industry provide the technology for increasingly personalized medicine, drug discovery, and disease ...